Post by BioKnow

The most interesting life sciences stories right now are not only about new therapies. They are also about the systems around them: how treatments are developed, how data infrastructure scales, how markets price innovation and how patients actually gain access. In this edition of Inside Biotech with BioKnow, we’re looking at: ➡️ A light-driven NADPH-generating nanotechnology platform being explored for ocular inflammation and oxidative stress. ➡️ USTR’s Section 301 investigation into Germany’s pharmaceutical pricing policies. ➡️ Bayer and AMD Silo AI advancing large-scale histopathology model training on AMD GPU infrastructure. ➡️ Bulgaria’s national medicines policy reform and the challenge of improving access to innovative therapies. Each story points to a different pressure shaping the sector. In ocular inflammation, researchers are exploring whether photosynthetic systems can be adapted to support redox balance in mammalian tissue. In pharmaceutical pricing, trade policy is becoming more closely tied to questions about who pays for innovation and how R&D costs are distributed globally. In AI-enabled R&D, companies are investing in the infrastructure needed to train and deploy complex models for fields like digital pathology. And in medicine access, countries like Bulgaria are confronting the tradeoff between cost control and timely availability of innovative therapies. The bigger picture is that drug development is becoming more dependent on the environment around the science. Strong research still matters. But so do reimbursement models, procurement systems, data architecture, policy strategy and global access planning. For biotech, pharma and life sciences leaders, these are the operational shifts worth watching. Which one do you think will have the greatest impact on the future of drug development? #LifeSciences #Biotech #Pharma #DrugDevelopment **This week’s edition of Inside Biotech with BioKnow is brought to you by The Galien Foundation